TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $32,534,016 | -17.1% | 2,118,100 | +21.4% | 0.59% | -23.4% |
| Q1 2023 | $39,229,307 | +48.9% | 1,744,300 | +39.2% | 0.77% | +52.8% |
| Q4 2022 | $26,353,324 | -14.7% | 1,253,130 | 0.0% | 0.50% | -12.0% |
| Q3 2022 | $30,877,000 | +65.0% | 1,253,130 | +62.3% | 0.57% | +69.0% |
| Q2 2022 | $18,710,000 | +41.9% | 772,200 | +46.2% | 0.34% | +175.6% |
| Q1 2021 | $13,187,000 | – | 528,100 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |